Genome-wide mapping of 5-hydroxymethylcytosine revealed its loss in melanoma, and restoring active TET2 or IDH2 reactivated 5-hydroxymethylcytosine suppressed melanoma growth and increased tumor-free survival in animal models, suggesting the therapeutic potential of targeting epigenetic changes [27,28]. This evidence concerns the gene TET2 and melanoma.